

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 廣州藥業股份有限公司

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **RESIGNATION OF EXECUTIVE DIRECTOR AND CHAIRMAN, APPOINTMENT OF CHAIRMAN AND CHANGE OF AUTHORIZED REPRESENTATIVE**

The Board announces that with effect from 8 August 2013:

- (1) Mr. Yang Rongming has resigned as an executive director, chairman of the Company and the chairman of the Strategic Development and Investment Committee. It follows that Mr. Yang Rongming also ceased to be the authorized representative of the Company;
- (2) Mr. Li Chuyuan, currently an executive director of the Company, has been appointed as chairman of the Company; and
- (3) Ms. Cheng Ning has been appointed as authorized representative of the Company.

## **RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN AND AUTHORIZED REPRESENTATIVE OF THE COMPANY**

The board of directors (the “Board”) of Guangzhou Pharmaceutical Company Limited (the “Company”) hereby announces that Mr. Yang Rongming (“Mr. Yang”) has resigned as an executive director, chairman of the Company and the chairman of the Strategic Development and Investment Committee with effect from 8 August 2013 as he has reached the age of statutory retirement. It follows that he also ceased to be the authorized representative of the Company on 8 August 2013.

Mr. Yang confirmed that there was no matter that need to be brought to the attention of the shareholders of the Company in relation to his resignation. The Board and Mr. Yang confirmed that (i) they were not aware of any personal obligations that Mr. Yang had given to the Company and its subsidiaries (collectively the “Group”) that would have affected the operation of the Group as a result of his resignation; and(ii) there was no disagreement in all aspects between the Company and Mr. Yang which would have caused the resignation of Mr. Yang.

The Board would like to take this opportunity to express its sincere appreciation and gratitude to Mr. Yang for his efforts and contributions to the Company during his tenure of office.

#### **APPOINTMENT OF CHAIRMAN**

Following the resignation of Mr. Yang, the Board is pleased to announce that Mr. Li Chuyuan (“Mr. Li”), currently an executive director of the Company, has been appointed as the chairman of the Company with effect from 8 August 2013.

#### **APPOINTMENT OF AUTHORIZED REPRESENTATIVE**

Following the resignation of Mr. Yang, the Board has also appointed Ms. Cheng Ning, currently an executive director of the Company, as the authorized representative of the Company with effect from 8 August 2013. After the resignation of Mr. Yang, the authorized representatives of the Company pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited are Mr. Li and Ms. Cheng Ning.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 8 August 2013

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*